ZIOPHARM Oncology Inc (ZIOP) Position Reduced by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. reduced its position in shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 2.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 131,722 shares of the biotechnology company’s stock after selling 2,695 shares during the quarter. Raymond James Financial Services Advisors Inc. owned approximately 0.09% of ZIOPHARM Oncology worth $819,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of ZIOP. Vanguard Group Inc. raised its holdings in ZIOPHARM Oncology by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after purchasing an additional 553,933 shares in the last quarter. State Street Corp raised its holdings in ZIOPHARM Oncology by 12.8% in the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock worth $28,342,000 after purchasing an additional 517,057 shares in the last quarter. Morgan Stanley raised its holdings in ZIOPHARM Oncology by 19.5% in the 1st quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock worth $12,610,000 after purchasing an additional 324,774 shares in the last quarter. California Public Employees Retirement System raised its holdings in ZIOPHARM Oncology by 95.9% in the 1st quarter. California Public Employees Retirement System now owns 435,532 shares of the biotechnology company’s stock worth $2,541,000 after purchasing an additional 213,166 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in ZIOPHARM Oncology in the 2nd quarter worth $1,010,000. Institutional investors own 41.91% of the company’s stock.

Several research analysts have commented on ZIOP shares. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the stock a “buy” rating in a report on Tuesday, August 1st. BidaskClub upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $16.50.

TRADEMARK VIOLATION NOTICE: “ZIOPHARM Oncology Inc (ZIOP) Position Reduced by Raymond James Financial Services Advisors Inc.” was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/10/29/ziopharm-oncology-inc-ziop-position-reduced-by-raymond-james-financial-services-advisors-inc.html.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) opened at 4.77 on Friday. ZIOPHARM Oncology Inc has a one year low of $4.40 and a one year high of $7.88. The firm has a 50-day moving average of $5.89 and a 200 day moving average of $6.14. The company’s market capitalization is $670.81 million.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. During the same quarter last year, the business posted ($1.01) earnings per share. The firm’s revenue for the quarter was down 5.9% compared to the same quarter last year. Equities research analysts predict that ZIOPHARM Oncology Inc will post ($0.56) earnings per share for the current fiscal year.

ZIOPHARM Oncology Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc (NASDAQ:ZIOP).

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

What are top analysts saying about ZIOPHARM Oncology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ZIOPHARM Oncology Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit